Breaking News, Promotions & Moves

Famar Names New CEO

Bruce Vielle joins the company following a seven-year tenure as CEO of Synerlab Group/Meribel Pharma Solutions.

Author Image

By: Charlie Sternberg

Associate Editor

Famar, a European contract development and manufacturing organization (CDMO), has appointed Bruce Vielle as Chief Executive Officer (CEO), effective August 3, 2026. He succeeds Dr. Riku Rautsola, who has led the company as interim CEO since autumn 2025 and who will work closely with Vielle to ensure a smooth transition.

“On behalf of the Board and MidEuropa, I am very pleased to welcome Bruce to Famar,” said Peter Prock, Chairman of Famar. “He is a proven CDMO leader with a strong track record in operational execution, sterile manufacturing and value creation, the experience Famar needs as we invest in new capabilities and become an even stronger and agile partner for our customers.”

Experience

Vielle has spent his career leading complex, multi-site manufacturing organizations. For the past seven years, he has been CEO of Synerlab Group and its successor, Meribel Pharma Solutions, most recently leading 2,000 employees across 13 manufacturing sites in France, Spain and Sweden.

Before that, he was Chief Operating Officer of Vétoquinol, a top-10 global animal health company, and he began his pharmaceutical career in site leadership roles at Unither. Throughout, he has served demanding, blue-chip pharmaceutical, biotech and medtech customers across a broad range of complex dosage forms, with a consistent focus on disciplined execution, quality and reliability of supply.

An engineer by training, Vielle holds an Executive MBA from HEC Paris and is an expert in Lean manufacturing and Six Sigma.

“I am delighted and energized to be joining Famar. This is a company with a strong European footprint, trusted customer relationships and talented people, and I see significant opportunity ahead of us,” Vielle remarked. “Our customers are growing, and Famar’s role is to grow with them by investing in the capabilities, capacity and service they need, from development through to commercial supply. I look forward to working with the leadership team and colleagues at every site to deliver for our customers.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters